“…Due to the structural similarity with nicotine, the pharmacological properties of both (−)- and (+)-isoanatabine were examined by Kem and co-workers at rat and human α4β2-nAChRs. 196 The binding affinity of (−)-isoanatabine (K i = 108 nM) at rat α4β2-nAChR was slightly stronger than the (+)-enantiomer (K i = 136 nM); however, at the human α4β2-nAChR, (−)-isoanatabine was less efficacious (EC 50 = 1.01 µM; I max = 78.7%) than the (+)-enantiomer (EC 50 = 0.31 µM; I max = 102%). 196 These findings indicate that isoanatabine is a more potent ACh stimulant at the α4β2-receptors relative to anabasine and anatabine, suggesting the presence and the position of the double bond improves nicotinic receptor binding.…”